Previous 10 | Next 10 |
Zetomipzomib added to stable background therapy reduced proteinuria by 50% or greater (ORR) in 11 of 17 patients (64.7%) reaching end of treatment at Week 25. This benefit occurred with a 53% mean reduction of background corticosteroid use. ORRs increased to 94.1% at Week 29...
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that four posters will be presented at the upcoming American Society of Nephrology’s (AS...
Clinical-stage biotech Kezar Life Sciences ( NASDAQ: KZR ) on Monday said its investigational new drug application for its inhibitor zetomipzomib for the treatment of autoimmune hepatitis (AIH) had been cleared by the U.S. FDA. AIH occurs when the body's immune system atta...
Company to host a virtual Research and Development Day during the fourth quarter 2022 Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announc...
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that three posters will be presented at the upcoming American College of Rheumatology (ACR) Con...
Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Christopher Kirk, PhD, Co-founder, President and Chief Scientific Officer, will p...
Gainer: Kinnate Biopharma ( KNTE ) +5% . Kezar Life Sciences ( KZR ) +5% . BridgeBio Pharma ( BBIO ) +5% . Stronghold Digital Mining ( SDIG ) +3% . IDEAYA Biosciences ( IDYA ) +3% . Losers: Advanced Emissions Solutions ( ...
Kezar Life Sciences press release ( NASDAQ: KZR ): Q2 GAAP EPS of -$0.25 beats by $0.02 . Cash, cash equivalents and marketable securities totaled $306.8 million. For further details see: Kezar Life Sciences GAAP EPS of -$0.25 beats by $0.02
Announced positive topline results from the MISSION Phase 2 Trial evaluating zetomipzomib for the treatment of patients with lupus nephritis Appointed Nick Mordwinkin, Pharm.D., Ph.D. as Chief Business Officer Cash, cash equivalents and marketable securities totaled ...
Over the past few days, there have been some monster moves across a number of Russell 3,000 stocks. Taking a look at the Russell 3,000 members that had at least been cut in half from the time of the index’s high on January 3rd through the low on June 16th, followed by a rally o...
News, Short Squeeze, Breakout and More Instantly...
Kezar Life Sciences Inc. Company Name:
KZR Stock Symbol:
NASDAQ Market:
Kezar Life Sciences Inc. Website:
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at...
PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of t...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...